A new strategy may allow myotubularin protein to enter muscle, with implications for X-linked myotubular myopathy and other diseases
posted on May 5, 2010 - 12:21pm
MDA-supported researchers at 4s3 Bioscience, a biotechnology company in Medford, Mass., are using a new molecular strategy to transport a potentially therapeutic protein into muscles, as an experimental treatment for X-linked myotubular myopathy (MTM), a genetic muscle disease that's generally fatal in infancy.
The treatment will be tested in a mouse model of MTM. These mice do not make...